187 related articles for article (PubMed ID: 36128805)
1. A Multicenter, Single-Blind, Case-Control, Immunohistochemical Study of Orbital Tissue in Thyroid Eye Disease.
Hai YP; Saeed MEM; Ponto KA; Elflein HM; Lee ACH; Fang S; Zhou H; Frommer L; Längericht J; Efferth T; Kahaly GJ
Thyroid; 2022 Dec; 32(12):1547-1558. PubMed ID: 36128805
[No Abstract] [Full Text] [Related]
2. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy.
Wang R; Song D; Zhong Y; Li H
BMC Immunol; 2024 May; 25(1):31. PubMed ID: 38734625
[TBL] [Abstract][Full Text] [Related]
3. It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease.
Girnita L; Smith TJ; Janssen JAMJL
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S1-S12. PubMed ID: 35167695
[TBL] [Abstract][Full Text] [Related]
4. IL-17A Promotes RANTES Expression, But Not IL-16, in Orbital Fibroblasts Via CD40-CD40L Combination in Thyroid-Associated Ophthalmopathy.
Fang S; Huang Y; Zhong S; Zhang Y; Liu X; Wang Y; Gu P; Zhou H; Fan X
Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6123-6133. PubMed ID: 27832278
[TBL] [Abstract][Full Text] [Related]
5. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients.
Wakelkamp IM; Bakker O; Baldeschi L; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 2003 Mar; 58(3):280-7. PubMed ID: 12608932
[TBL] [Abstract][Full Text] [Related]
6. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.
Kumar S; Schiefer R; Coenen MJ; Bahn RS
Thyroid; 2010 Jan; 20(1):59-65. PubMed ID: 20017620
[TBL] [Abstract][Full Text] [Related]
7. Forkhead Transcription Factor FOXO1 Is Regulated by Both a Stimulatory Thyrotropin Receptor Antibody and Insulin-Like Growth Factor-1 in Orbital Fibroblasts from Patients with Graves' Ophthalmopathy.
Kumar S; Coenen M; Iyer S; Bahn RS
Thyroid; 2015 Oct; 25(10):1145-50. PubMed ID: 26213859
[TBL] [Abstract][Full Text] [Related]
8. Orbital Angiogenesis and Lymphangiogenesis in Thyroid Eye Disease: An Analysis of Vascular Growth Factors with Clinical Correlation.
Wong LL; Lee NG; Amarnani D; Choi CJ; Bielenberg DR; Freitag SK; D'Amore PA; Kim LA
Ophthalmology; 2016 Sep; 123(9):2028-36. PubMed ID: 27423310
[TBL] [Abstract][Full Text] [Related]
9. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.
Khong JJ; McNab AA; Ebeling PR; Craig JE; Selva D
Br J Ophthalmol; 2016 Jan; 100(1):142-50. PubMed ID: 26567024
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
13. Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.
Gulbins A; Horstmann M; Keitsch S; Soddemann M; Wilker B; Wilson GC; Zeidan R; Hammer GD; Daser A; Bechrakis NE; Görtz GE; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1252727. PubMed ID: 37810891
[TBL] [Abstract][Full Text] [Related]
14. M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.
Lu Y; Wang Y; Wang Y; Wu Y; Huang Y; Liu X; Zhang S; Zhong S; Li Y; Li B; Sun J; Fang S; Zhou H
Thyroid; 2023 Mar; 33(3):338-350. PubMed ID: 36617890
[No Abstract] [Full Text] [Related]
15. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.
Ugradar S; Shi L; Wang Y; Mester T; Yang H; Douglas RS
Eye (Lond); 2021 Sep; 35(9):2607-2612. PubMed ID: 33221815
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
Krieger CC; Sui X; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1653-e1660. PubMed ID: 34788857
[TBL] [Abstract][Full Text] [Related]
17. TSHR Signaling Stimulates Proliferation Through PI3K/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts.
Woeller CF; Roztocil E; Hammond C; Feldon SE
Invest Ophthalmol Vis Sci; 2019 Oct; 60(13):4336-4345. PubMed ID: 31622470
[TBL] [Abstract][Full Text] [Related]
18. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
20. Future Projections in Thyroid Eye Disease.
Barbesino G; Salvi M; Freitag SK
J Clin Endocrinol Metab; 2022 Aug; 107(Suppl_1):S47-S56. PubMed ID: 36346684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
